<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049776</url>
  </required_header>
  <id_info>
    <org_study_id>ILCC #2 IllinoisCancerCare #2</org_study_id>
    <nct_id>NCT01049776</nct_id>
  </id_info>
  <brief_title>GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line</brief_title>
  <official_title>A Phase II Study of GW786034 in Patients With Non Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens. An Institutional Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Illinois CancerCare, P.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Illinois CancerCare, P.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung Cancer is the most common cause of cancer death in the United States with an estimated
      mortality in excess of 160,000, more than the combined mortality seen with prostate, breast,
      colorectal cancers(1). Most patients with Lung Cancer have Non-Small Cell Lung Cancers(
      NSCLC) and only 25-30% of patients with NSCLC (Non Small Cell Lung Cancer) have resectable
      disease( Stage I or II) at the time of diagnosis.

      The vast majority of patients with advanced NSCLC (Non Small Cell Lung Cancer) are not
      curable and overall five year survival is 11%-14%1.

      Chemotherapy is beneficial for patients with locally advanced and metastatic disease.
      Numerous phase III studies have determined the superiority of systemic chemotherapy over best
      supportive care. Platinum based chemotherapy has been widely accepted as the standard of care
      for the initial treatment of advanced NSCLC.

      However first line chemotherapy is modest at best. A randomized trial comparing four of the
      most commonly used chemotherapy regimens in the United States not only failed to show a
      clearly superior arm but also confirmed the dismal prognosis of these patients. The response
      rate for all 1207 patients was 18.6% with a median survival of eight months and one year
      survival of 33.5 % and a two year survival of 12%5. Clearly a different paradigm is needed
      for the treatment of this disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Better therapies for patients with NSCLC (Non Small Cell Lung Cancer) who progress after
      initial chemotherapy is urgently needed.

      Besides VEGF (vascular endothelial growth factor), human lung cancers are known to express
      PDGFR (platelet-derived growth factor receptors). NSCLC, like most cancers, involves defects
      in signal transduction pathways. Receptor tyrosine kinases (RTKs) play a pivotal role in
      these signaling pathways, transmitting extracellular molecular signals into the cytoplasm
      and/or nucleus of a cell. Among such RTKs are the receptors for polypeptide growth factors
      such as epidermal growth factor (EGF), insulin, platelet-derived growth factor (PDGF),
      neurotrophins (i.e., NGF), and fibroblast growth factor (FGF). Phosphorylation of such RTKs
      activates their cytoplasmic domain kinase function, which in turns activates downstream
      signaling molecules. Thus, RTKs are key mediators of cellular signaling as well as
      oncogenesis resulting from over-expression and activation of such RTKs and their substrates.
      Due to their pivotal role in normal and aberrant signaling, RTKs are the subject of
      increasing focus as potential drug targets for the treatment of certain types of cancer. For
      example, Herceptin.RTM., an inhibitor of HER2/neu, is currently an approved therapy for a
      certain subset of breast cancer. Iressa.TM. (ZD1839) and Tarceva.TM. (OSI-774), both
      small-molecule inhibitors of EGFR, have been approved for the treatment of NSCLC.

      Platelet-derived growth factor (PDGF) and its receptors (PDGFRs) are a family of RTKs that
      play an important role in the regulation of normal cell growth and differentiation. PDGFRs
      are involved in a variety of pathological processes, including atherosclerosis, neoplasia,
      tissue repair, and inflammation. PDGFRs, which consist of two isoforms (alpha and beta), are
      membrane protein-tyrosine kinases that, upon binding to PDGF, become activated and, via
      recruitment of SH domain-containing effector molecules, initiate distinct or overlapping
      signaling cascades that coordinate cellular responses.

      Expression of a constitutively active PDGFR leads to cellular transformation and suggests
      that, in normal cells, PDGFR activity must be tightly regulated to oppose continuous
      activation of its downstream effectors. PDGFR beta, for example, is known to be
      over-expressed in a large number of tumors, and PDGF treatment causes transformation and
      malignant tumors in a variety of experimental systems. One study reported the apparent
      expression of PDGFR alpha in nearly 100% of human lung cancer tumors examined, and reported
      the growth inhibition of a lung cancer cell line, A549, by Gleevec, an effect that was
      surmised to be mediated via PDGFR inhibition.

      Donnem et al evaluated 335 resected patients with stage I to III with NSCLC. Using IHC
      (immunohistochemical staining) the expression of PDGF-A, -B, -C and -D along with PDGFR alpha
      and beta. In multivariant analysis high tumor cell expression of PDGF-B and PDGF- alpha were
      independent negative prognostic predictors. They suggested that PDGF inhibition may be an
      option for treatment of NSCLC.

      Socinski et al recently described the activity of sunitnib malate (SU11248) an oral,
      multitargeted tyrosine kinase inhibitor targeting VEGFR, PDGFR, KIT, FLT3 and RET on tumor
      cells, tumor neovasculature and pericytes. In an open-label, two-stage, multicenter phase II
      trial evaluating the single-agent activity of sunitinib in refractory NSCLC, patients with
      confirmed diagnosis of NSCLC, ECOG PS 0-1, no recent gross hemoptysis, no brain metastases,
      patients (pts) previously treated with 1-2 chemotherapy regimens, and adequate end-organ
      function, pts received sunitinib at 50 mg/day po for 4 weeks (wks) followed by 2 wks off
      treatment (6 wks considered a cycle). A total of 64 pts were enrolled and 63 pts treated. Six
      confirmed partial responses have been observed among 63 treated patients. Stable disease has
      been observed in an additional 12 pts (19.0% of all treated patients). Based on this study,
      Sunitinib appeared to have single-agent activity in previously treated pts with recurrent and
      advanced NSCLC, with the level of activity similar to currently approved agents. Sunitinib
      was well tolerated in this population. The trial was extended to explore a continuous dosing
      strategy of sunitinib at 37.5 mg/day po.

      In addition to VEGF and PDGFR, expression of c-kit has been described in NSCLC. Moreover, it
      has been found to have an effect on survival. Micke et al, stained the tumor tissue of 95
      consecutive patients with adenocarcinoma of the lung, using a polyclonal c-kit antibody.
      c-kit expression was correlated with relevant clinical parameters obtained by chart review.
      Positive c-kit expression in tumor tissue was observed in 61 of 95 patients (64%). Univariate
      analysis showed a significant effect of T (p = 0.003), N (p = 0.001) and M stage (p &lt; 0.001)
      as well as of performance status (p = 0.001), surgical resection (p &lt; 0.001), and LDH serum
      levels (p = 0.016) on survival. In contrast, c-kit protein expression was non- significant (p
      = 0.913). However, multivariate Cox regression with the influential parameters revealed a
      significant effect of c-kit expression on survival. They concluded that, the receptor
      tyrosine kinase c-kit is frequently expressed in adenocarcinomas of the lung and has a
      relevant effect on patient survival. They also concluded that the results of this study
      support clinical trials targeting the c-kit receptor with specific c-kit inhibitors.

      Combined blockade of VEGF, PDGFR and c-kit may result in better outcomes for patients with
      Non Small Cell Lung Carcinoma.

      Pazopanib is a novel, orally active small molecule inhibitor targeting multiple tyrosine
      kinases including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha and - beta, and c-kit. An antitumor
      effect due to inhibiting of the VEGF driven angiogenic pathway is well established. In
      addition to its effects on VEGF receptors, pazopanib targets additional tyrosine kinases
      including PDGF receptors and c-kit that have established roles in tumorigenesis and oncogenic
      mutations in both have been described. Preliminary data from a phase I study of pazopanib in
      patients with solid tumors demonstrated early evidence of antitumor activity. Among 43
      patients enrolled, a minimal response occurred in 4 patients and stable disease &gt;6 months,
      was observed in an additional 6 patients.

      Pazopanib was well tolerated at doses up to 2000 mg daily. Pazopanib is a potent and
      selective, orally available, small molecule inhibitor of VEGFR-1, -2, and -3, PDGF-α, PDGF-β,
      and c-kit tyrosine kinases (TKs). The agent selectively inhibits proliferation of endothelial
      cells stimulated with VEGF but not with basic fibroblast growth factor. In non-clinical
      angiogenesis models, pazopanib inhibited VEGF-dependent angiogenesis in a dose-dependent
      manner and in xenograft tumor models, twice-daily administration of pazopanib significantly
      inhibited tumor growth in mice implanted with various human tumor cells. Upon chronic oral
      dosing, pazopanib is expected to inhibit VEGF driven angiogenesis and as a consequence, limit
      solid tumor growth. Because angiogenesis is necessary for the growth and metastasis of solid
      tumors, and VEGF is believed to have a pivotal role in this process, pazopanib treatment may
      have broad-spectrum clinical utility.

      Based on its ability to target multiple tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3,
      PDGFR-alpha and beta and c-kit, which have been implicated in non small cancer, investigation
      of Pazopanib in patients with non small cell lung cancer is warranted.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated due to positive results seen in statistical analysis. Adequate patient
    enrollment was achieved.
  </why_stopped>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Non Small Cell Lung Cancer Participants With Disease Control (Complete Response+Partial Response+Stable Disease) Based on RECIST 1.0 Measured by CT or MRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions: Partial Response (PR), &gt;= 30% decrease in the sum of the longest diameter of target lesion, taking as reference the baseline sum of the longest diameter: Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum Longest Diameter since the treatment started</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Describe the Clinical Toxicity Profile of Pazopanib in This Particular Patient Population</measure>
    <time_frame>after the first 6 patients and quarterly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pazapanib (GW786034)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib (GW786034)</intervention_name>
    <description>Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months</description>
    <arm_group_label>Pazapanib (GW786034)</arm_group_label>
    <other_name>Pazopanib monohydrochloride salt GW786034</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Required Characteristics 3.1. Subjects must provide written informed consent prior to
        performance of study-specific procedures or assessments, and must be willing to comply with
        treatment and follow up. Procedures conducted as part of the subject's routine clinical
        management (e.g., blood count, imaging study) and obtained prior to signing of informed
        consent may be utilized for screening or baseline purposes provided these procedures are
        conducted as specified in the protocol.

        Note: It is not necessary that informed consent be obtained within the protocol-specified
        screening window.

        3.11 ≥18 years of age.

        3.12 ≥2 prior systemic therapies for Non Small Cell Lung Cancer.

        3.13 Histologic or cytologic diagnosis of stage IV Non Small Cell Lung cancer

        . 3.14 Measurable disease. For patients having only lesions measuring ≥1 cm to ≤2 cm per
        RECIST criteria must use spiral CT imaging for both pre- and post-treatment tumor
        assessments.

        3.15 Laboratory values obtained ≤14 days prior to registration: Hematologic Absolute
        neutrophil count (ANC) 1.5 X 109/L Hemoglobin1 9 g/dL (5.6 mmol/L) Platelets 100 X 109/L
        Prothrombin time (PT) or international normalized ratio (INR) 1.2 X upper limit of normal
        (ULN) Partial thromboplastin time (PTT) 1.2 X ULN Hepatic2 Total bilirubin 1.5 X ULN AST
        and ALT 2.5 X ULN Renal Serum creatinine 1.5 mg/dL (133 µmol/L)

        Or, if greater than 1.5 mg/dL:

        Calculated creatinine clearance 50 mL/min

        Urine Protein to Creatinine Ratio (UPC)3 &lt; 1

          1. Subjects may not have had a transfusion within 7 days of screening assessment.

          2. Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN are not permitted

          3. If UPC &gt;/= 1, then a 24-hour urine protein must be assessed. Subjects must have a
             24-hour urine protein value &lt;1g to be eligible.

             3.16 ECOG Performance Score 0, or 1.

             3.17 Negative pregnancy test done ≤ 7 days prior to registration, for women of
             childbearing potential only.

             A female is eligible to enter and participate in this study if she is of:
             Non-childbearing potential (i.e., physiologically incapable of becoming pregnant),
             including any female who has had:

               -  A hysterectomy

               -  A bilateral oophorectomy (ovariectomy)

               -  A bilateral tubal ligation

               -  Is post-menopausal

             Subjects not using hormone replacement therapy (HRT) must have experienced total
             cessation of menses for ≥ 1 year and be greater than 45 years in age, OR, in
             questionable cases, have a follicle stimulating hormone (FSH) value &gt;40 mIU/mL and an
             estradiol value &lt; 40pg/mL (&lt;140 pmol/L).

             Subjects using HRT must have experienced total cessation of menses for &gt;= 1 year and
             be greater than 45 years of age OR have had documented evidence of menopause based on
             FSH and estradiol concentrations prior to initiation of HRT

             Childbearing potential, including any female who has had a negative serum pregnancy
             test within 1 week prior to the first dose of study treatment, preferably as close to
             the first dose as possible, and agrees to use adequate contraception. GSK acceptable
             contraceptive methods, when used consistently and in accordance with both the product
             label and the instructions of the physician, are as follow:

               -  An intrauterine device with a documented failure rate of less than 1% per year.

               -  Vasectomized partner who is sterile prior to the female subject's entry and is
                  the sole sexual partner for that female.

               -  Complete abstinence from sexual intercourse for 14 days before exposure to
                  investigational product, through the dosing period, and for at least 21 days
                  after the last dose of investigational product.

               -  Double-barrier contraception (condom with spermicidal jelly, foam suppository, or
                  film; diaphragm with spermicide; or male condom and diaphragm with spermicide).

               -  Oral contraceptives

               -  Female subjects who are lactating should discontinue nursing prior to the first
                  dose of study drug and should refrain from nursing throughout the treatment
                  period and for 14 days following the last dose of study drug

             3.18 Ability and willingness to provide informed consent.

             3.19 Life expectancy ≥12 weeks.

             Exclusion Criteria:

             3.21 Any of the following as this regimen may be harmful to a developing fetus or
             nursing child.

             • Pregnant women

               -  Nursing women

               -  Men or women of childbearing potential or their sexual partners who are unwilling
                  to employ adequate contraception.

             3.22 Any abnormal serum calcium, magnesium, and potassium levels

             3.23 Clinically significant hemoptysis, cerebral hemorrhage, or gastrointestinal
             hemorrhage in the past 6 months

             3.24 Any patient currently on an antiarrhythmics or other medications that are know to
             prolong the QT interval.

             3.25 Uncontrolled infection.

             3.26 Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140
             mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg].

             Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to
             study entry. BP must be re-assessed on two occasions that are separated by a minimum
             of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values from
             each BP assessment must be &lt;140/90 mmHg in order for a subject to be eligible for the
             study

             3.27 Any condition (e.g., gastrointestinal tract disease resulting in an inability to
             take oral medication or a requirement for IV alimentation, prior surgical procedures,
             affecting absorption, or active peptic ulcer disease) that impairs their ability to
             swallow and retain pazopanib tablets.

               -  Malabsorption syndrome

               -  Major resection of the stomach or small bowel. 3.28 Clinically significant
                  gastrointestinal abnormalities that may increase the risk for gastrointestinal
                  bleeding including, but not limited to:

               -  Active peptic ulcer disease

               -  Known intraluminal metastatic lesion/s with risk of bleeding

               -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other
                  gastrointestinal conditions with increased risk of perforation

               -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal
                  abscess within 28 days prior to beginning study treatment.

             3.29 Known endobronchial lesions and or lesions infiltrating major pulmonary vessels.

             3.30 Cavitary lesions deemed to be at increased risk of bleeding.

             3.31 Any other severe underlying diseases that are, in the judgment of the
             investigator, inappropriate for entry into this study.

             3.32 Second primary malignancy except for carcinoma in situ of the cervix or
             nonmelanomatous skin cancer, unless that prior malignancy was diagnosed and
             definitively treated ≥5 years previously with no subsequent evidence of recurrence.
             Patients with a history of low-grade (Gleason score ≤6) localized prostate cancer will
             be eligible even if diagnosed &lt;5 years prior to registration.

             3.33 Any ancillary therapy considered investigational (utilized for a non-FDA approved
             indication and in the context of a research investigation) ≤4 weeks prior to
             registration.

             3.34 Other concurrent chemotherapy, immunotherapy, radiotherapy.

             3.35a. History of allergic reactions attributed to compounds of similar chemical or
             biologic composition to pazopanib or other agents used in the study.

             b. Medications that act through the CYP450 system. Some medications that act through
             the cytochrome P450 system are specifically prohibited in patients receiving
             pazopanib. Certain other agents should be used with caution. (A list of medications
             that are specifically prohibited or that should be used with caution during this trial
             of pazopanib will be provided with the full study protocol as Appendix 1. A list of
             selected agents that could affect pazopanib will be listed in Appendix I. ) c. Any of
             the following concurrent severe and/or uncontrolled medical conditions:

             • Serious or non-healing wound, ulcer, or bone fracture

             • History of abdominal fistula, diverticulosis, gastrointestinal perforation, or
             intra-abdominal abscess ≤28 days prior to registration

               -  Any history of cerebrovascular accident (CVA) ≤6 months prior to registration

               -  History of any one or more of the following cardiovascular conditions within the
                  past 6 months:

               -  Cardiac angioplasty or stenting

               -  Myocardial infarction

               -  Unstable angina

               -  Coronary artery bypass graft surgery

               -  Symptomatic peripheral vascular disease

               -  Class III or IV congestive heart failure, as defined by the New York Heart
                  Association (NYHA)

               -  History of venous thrombosis ≤12 weeks prior to registration.

               -  Class III or IV heart failure as defined by the NYHA functional classification
                  system .History of Class II heart failure and is asymptomatic on treatment may be
                  considered eligible.

               -  Poorly controlled diabetes.

               -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the
                  lung.

               -  QTc prolongation (defined as a QTc interval ) &gt; 480 msecs using Bazett's formula)
                  or other significant ECG abnormalities d. Symptomatic, untreated, or uncontrolled
                  CNS metastases or seizure disorder. Patients with CNS metastases treated with
                  whole brain radiation (WBRT)or gamma knife may be enrolled after completion of
                  WBRT or gamma knife. Patients may begin chemotherapy as early as the next day
                  after completion of WBRT or gamma knife.

                  e. Uncontrolled intercurrent illness including, but not limited to, ongoing or
                  active infection or psychiatric illness/social situations that would limit
                  compliance with study requirements.

                  f. HIV-positive patients on combination antiretroviral therapy because of the
                  potential for pharmacokinetic interactions with pazopanib. In addition, these
                  patients are at increased risk of lethal infections when treated with marrow
                  suppressive therapy

                  g. Any of the following prior therapies:

               -  Major surgery (i.e., laparotomy), open biopsy, or significant traumatic injury ≤4
                  weeks prior to registration. Minor surgery ≤4 weeks prior to registration.
                  Insertion of a vascular access device is not considered major or minor surgery in
                  this regard.

               -  Treatment with any of the following anti-cancer therapies:

               -  radiation therapy, surgery or tumor embolization within 14 days prior to the
                  first dose of Pazopanib OR

               -  chemotherapy, immunotherapy, biologic therapy, investigational therapy or
                  hormonal therapy within 14 days or five half-lives of a drug (whichever is
                  longer) prior to the first dose of pazopanib

             Patients with progressive disease inside of the radiation field are not eligible.

             3.36 History of cerebrovascular accident including transient ischemic attack (TIA),
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.

             Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating
             agents for at least 6 weeks are eligible

             3.37 Evidence of active bleeding or bleeding diathesis.

             3.38 Hemoptysis within 6 weeks of first dose of study drug.

             3.39 Unable or unwilling to discontinue use of prohibited medications for at least 14
             days or five half-lives of a drug (whichever is longer) prior to the first dose of
             study drug and for the duration of the study.

             3.40 Any ongoing toxicity from prior anti-cancer therapy that is &gt;Grade 1 and/or that
             is progressing in severity, except alopecia.

             3.41 Other Eligibility Criteria Considerations To assess any potential impact on
             subject eligibility with regard to safety, the investigator must refer to the
             following document(s) for detailed information regarding warnings, precautions,
             contraindications, adverse events, and other significant data pertaining to the
             investigational product(s) being used in this study: Clinical Investigator's Brochure
             for pazopanib.[Investigator Brochure]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sachdev P. Thomas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Illinois CancerCare, P.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Canton</city>
        <state>Illinois</state>
        <zip>61520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Carthage</city>
        <state>Illinois</state>
        <zip>62321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Eureka</city>
        <state>Illinois</state>
        <zip>61530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Macomb</city>
        <state>Illinois</state>
        <zip>61455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Monmouth</city>
        <state>Illinois</state>
        <zip>61462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Pekin</city>
        <state>Illinois</state>
        <zip>61554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Peru</city>
        <state>Illinois</state>
        <zip>61354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare, P.C.</name>
      <address>
        <city>Princeton</city>
        <state>Illinois</state>
        <zip>61356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <results_first_submitted>August 11, 2014</results_first_submitted>
  <results_first_submitted_qc>September 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2014</results_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Illinois CancerCare, P.C.</investigator_affiliation>
    <investigator_full_name>Sachdev Thomas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lung Cancer Non Small Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pazapanib (GW786034)</title>
          <description>Pazopanib (GW786034): Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Stratification was performed based on histology of disease. Enrollment was targeted to 21 patients with squamous histology and 21 patients with non- squamous histology. Due to the lack of patients with squamous histology, the study was closed prior to meeting the enrollment goal of 44 subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Pazapanib (GW786034)</title>
          <description>Pazopanib (GW786034): Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Non Small Cell Lung Cancer Participants With Disease Control (Complete Response+Partial Response+Stable Disease) Based on RECIST 1.0 Measured by CT or MRI</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions: Partial Response (PR), &gt;= 30% decrease in the sum of the longest diameter of target lesion, taking as reference the baseline sum of the longest diameter: Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum Longest Diameter since the treatment started</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pazapanib (GW786034)</title>
            <description>Pazopanib (GW786034): Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Non Small Cell Lung Cancer Participants With Disease Control (Complete Response+Partial Response+Stable Disease) Based on RECIST 1.0 Measured by CT or MRI</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions: Partial Response (PR), &gt;= 30% decrease in the sum of the longest diameter of target lesion, taking as reference the baseline sum of the longest diameter: Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum Longest Diameter since the treatment started</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="0.21" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Describe the Clinical Toxicity Profile of Pazopanib in This Particular Patient Population</title>
        <time_frame>after the first 6 patients and quarterly</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pazapanib (GW786034)</title>
          <description>Pazopanib (GW786034): Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <description>lymphopenia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <description>nonspecific T-wave abnormality</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow- AML</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Albumin, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>ALT (SGPT)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>AST (SGOT)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Calcium, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Calcium, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Glomerular Filtration Rate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Glucose, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Glucose, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Magnesium, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Magnesium, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Phosphate, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Potassium, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Potassium, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sodium, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sodium, serum- low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Triglyceride, serum- high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrythmia- Systolic Anterior Motion</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cardiac Troponin I</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Left Ventricular Systolic Dysfunction (LVSD)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mitral Regurgitation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Prolonged QTc Interval</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Supraventricular and Nodal Arrhthymia- Atrial Fibrillation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Supraventricular and Nodal Arrhthymia- Sinus Bradycardia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Supraventricular and Nodal Arrhthymia- Sinus Tachycardi</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ventricular Arrythmia- PVCs</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes/Flushes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Thyroid Function, low</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Thyroid Function, high</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision- Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vision- Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vision- Flashing Lights/Floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Watery Eyes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dry Mouth/Salivary Gland</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Heartburn/Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Taste Alteration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Distention/Bloating- Abdominal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI- Lower GI NOS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rigors/Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU- Urinary NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Pulmonary/Upper Respiratory- Nose</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Abdomen</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Back</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Bone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Chest</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- External Ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Extremity, Limb</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Joint</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Muscle</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Neck</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- General NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pain- Shoulder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Syndromes- Systemic Inflammatory Response System (SIRS)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Dysfunction/Failure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Blood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Lung (Pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Respiratory Tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Sinus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Thrush</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Upper Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Urinary Tract</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Upper Airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infection- Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Muscle Weakness- generalized</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Muscle Weakness- upper extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue- Leg Cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue- Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue- Plantar Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Laryngeal Nerve Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mood Alteration- Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neurology- Tremors</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neuropathy: Motor</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neuropathy: Sensory</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Syncope (Fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mood Alteration- Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Somnolence/Depressed Level of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Incontinence, Urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Urinary Frequency/Urgency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, Pulmonary/Upper Respiratory- Respiratory Tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Bronchospasm/Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Voice Changes/Dysathria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hiccoughs (Hiccups/Singultus)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pneumonitis/Pulmonary Infiltrates</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nail Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the lack of patients with squamous histology, the study was closed prior to meeting the enrollment goal of 44 subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sachdev Thomas, M.D.</name_or_title>
      <organization>Illinois CancerCare, P.C.</organization>
      <phone>309-243-3000</phone>
      <email>sthomas@illinoiscancercare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

